睡眠呼吸暂停风险评估（SARA）的设计和验证：一种中重度阻塞性睡眠呼吸暂停的筛查工具。

IF 3 2区医学 Q2 CLINICAL NEUROLOGY

Nature and Science of Sleep Pub Date : 2025-06-04 eCollection Date: 2025-01-01 DOI:10.2147/NSS.S518391

Sarka Solecka, Hana Tomaskova, Milos Chudy, Tomas Kostlivy, Jana Slonkova

{"title":"睡眠呼吸暂停风险评估（SARA）的设计和验证：一种中重度阻塞性睡眠呼吸暂停的筛查工具。","authors":"Sarka Solecka, Hana Tomaskova, Milos Chudy, Tomas Kostlivy, Jana Slonkova","doi":"10.2147/NSS.S518391","DOIUrl":null,"url":null,"abstract":"Purpose: We designed and validated a concise, efficient screening tool, the Sleep Apnea Risk Assessment (SARA), to identify patients at high risk of moderate to-severe obstructive sleep apnea.Patients and methods: We conducted a two-phase, multicenter study from September 1, 2018, to October 31, 2023. We created Cohort A (n=221, mean age 50.5±13.0 years, 69.2% male) to design SARA and compared the results with the Epworth Sleepiness Scale, Berlin Questionnaire, Pittsburgh Sleep Quality Index, STOP-Bang, and STOP questionnaires. Cohort B (n=253, mean age 48.0±13.4 years, 75.5% male) served for validation.Results: SARA comprises six variables with the highest accuracy: sleep apnea observed by the bedroom partner (8 points), snoring (5 points), male sex (3 points), age≥50 years (3 points), daytime fatigue (3 points), and body mass index≥30 kg/m2 (2 points). SARA yielded an area under the receiver operating characteristic curve (AUC) of 0.77 (95% CI: 0.71-0.83) and sensitivity of 87.2% (95% CI: 80.8-92.1) in cohort A at a cut-off score of ≥11 points. Validation in cohort B showed an AUC of 0.79 (95% CI: 0.74-0.84) and a sensitivity of 98% (95% CI: 89.2-95.4). SARA performance significantly outperformed the other questionnaires tested.Conclusion: The SARA is a promising new screening tool for moderate-to-severe obstructive sleep apnea, demonstrating high sensitivity and a strong ROC curve. Further large-scale validation is recommended.","PeriodicalId":18896,"journal":{"name":"Nature and Science of Sleep","volume":"17 ","pages":"1163-1174"},"PeriodicalIF":3.0000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12145793/pdf/","citationCount":"0","resultStr":"{\"title\":\"Design and Validation of Sleep Apnea Risk Assessment (SARA): A Screening Tool for Moderate-to-Severe Obstructive Sleep Apnea.\",\"authors\":\"Sarka Solecka, Hana Tomaskova, Milos Chudy, Tomas Kostlivy, Jana Slonkova\",\"doi\":\"10.2147/NSS.S518391\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose: We designed and validated a concise, efficient screening tool, the Sleep Apnea Risk Assessment (SARA), to identify patients at high risk of moderate to-severe obstructive sleep apnea.Patients and methods: We conducted a two-phase, multicenter study from September 1, 2018, to October 31, 2023. We created Cohort A (n=221, mean age 50.5±13.0 years, 69.2% male) to design SARA and compared the results with the Epworth Sleepiness Scale, Berlin Questionnaire, Pittsburgh Sleep Quality Index, STOP-Bang, and STOP questionnaires. Cohort B (n=253, mean age 48.0±13.4 years, 75.5% male) served for validation.Results: SARA comprises six variables with the highest accuracy: sleep apnea observed by the bedroom partner (8 points), snoring (5 points), male sex (3 points), age≥50 years (3 points), daytime fatigue (3 points), and body mass index≥30 kg/m2 (2 points). SARA yielded an area under the receiver operating characteristic curve (AUC) of 0.77 (95% CI: 0.71-0.83) and sensitivity of 87.2% (95% CI: 80.8-92.1) in cohort A at a cut-off score of ≥11 points. Validation in cohort B showed an AUC of 0.79 (95% CI: 0.74-0.84) and a sensitivity of 98% (95% CI: 89.2-95.4). SARA performance significantly outperformed the other questionnaires tested.Conclusion: The SARA is a promising new screening tool for moderate-to-severe obstructive sleep apnea, demonstrating high sensitivity and a strong ROC curve. Further large-scale validation is recommended.\",\"PeriodicalId\":18896,\"journal\":{\"name\":\"Nature and Science of Sleep\",\"volume\":\"17 \",\"pages\":\"1163-1174\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-06-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12145793/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature and Science of Sleep\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/NSS.S518391\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature and Science of Sleep","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/NSS.S518391","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的：我们设计并验证了一种简洁、高效的筛查工具——睡眠呼吸暂停风险评估（SARA），以识别中度至重度阻塞性睡眠呼吸暂停的高风险患者。患者和方法：我们于2018年9月1日至2023年10月31日进行了一项两期多中心研究。我们创建A队列221人（平均年龄50.5±13.0岁，男性69.2%）设计SARA，并将结果与Epworth嗜睡量表、Berlin问卷、Pittsburgh睡眠质量指数、STOP- bang和STOP问卷进行比较。队列B （n=253，平均年龄48.0±13.4岁，男性75.5%）用于验证。结果：SARA包含6个准确度最高的变量：同寝伴侣观察到的睡眠呼吸暂停（8分）、打鼾（5分）、男性（3分）、年龄≥50岁（3分）、白天疲劳（3分）、体重指数≥30 kg/m2（2分）。在A队列中，SARA的受试者工作特征曲线下面积（AUC）为0.77 (95% CI: 0.71-0.83)，灵敏度为87.2% (95% CI: 80.8-92.1)，临界值≥11分。队列B的验证显示AUC为0.79 (95% CI: 0.74-0.84)，灵敏度为98% （95% CI: 89.2-95.4）。SARA的表现明显优于其他测试问卷。结论：SARA是一种有前景的中重度阻塞性睡眠呼吸暂停筛查新工具，具有较高的灵敏度和较强的ROC曲线。建议进一步进行大规模验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Design and Validation of Sleep Apnea Risk Assessment (SARA): A Screening Tool for Moderate-to-Severe Obstructive Sleep Apnea.

Purpose: We designed and validated a concise, efficient screening tool, the Sleep Apnea Risk Assessment (SARA), to identify patients at high risk of moderate to-severe obstructive sleep apnea.

Patients and methods: We conducted a two-phase, multicenter study from September 1, 2018, to October 31, 2023. We created Cohort A (n=221, mean age 50.5±13.0 years, 69.2% male) to design SARA and compared the results with the Epworth Sleepiness Scale, Berlin Questionnaire, Pittsburgh Sleep Quality Index, STOP-Bang, and STOP questionnaires. Cohort B (n=253, mean age 48.0±13.4 years, 75.5% male) served for validation.

Results: SARA comprises six variables with the highest accuracy: sleep apnea observed by the bedroom partner (8 points), snoring (5 points), male sex (3 points), age≥50 years (3 points), daytime fatigue (3 points), and body mass index≥30 kg/m² (2 points). SARA yielded an area under the receiver operating characteristic curve (AUC) of 0.77 (95% CI: 0.71-0.83) and sensitivity of 87.2% (95% CI: 80.8-92.1) in cohort A at a cut-off score of ≥11 points. Validation in cohort B showed an AUC of 0.79 (95% CI: 0.74-0.84) and a sensitivity of 98% (95% CI: 89.2-95.4). SARA performance significantly outperformed the other questionnaires tested.

Conclusion: The SARA is a promising new screening tool for moderate-to-severe obstructive sleep apnea, demonstrating high sensitivity and a strong ROC curve. Further large-scale validation is recommended.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature and Science of Sleep Neuroscience-Behavioral Neuroscience

CiteScore

5.70

自引率

5.90%

发文量

245

审稿时长

16 weeks

期刊介绍： Nature and Science of Sleep is an international, peer-reviewed, open access journal covering all aspects of sleep science and sleep medicine, including the neurophysiology and functions of sleep, the genetics of sleep, sleep and society, biological rhythms, dreaming, sleep disorders and therapy, and strategies to optimize healthy sleep. Specific topics covered in the journal include: The functions of sleep in humans and other animals Physiological and neurophysiological changes with sleep The genetics of sleep and sleep differences The neurotransmitters, receptors and pathways involved in controlling both sleep and wakefulness Behavioral and pharmacological interventions aimed at improving sleep, and improving wakefulness Sleep changes with development and with age Sleep and reproduction (e.g., changes across the menstrual cycle, with pregnancy and menopause) The science and nature of dreams Sleep disorders Impact of sleep and sleep disorders on health, daytime function and quality of life Sleep problems secondary to clinical disorders Interaction of society with sleep (e.g., consequences of shift work, occupational health, public health) The microbiome and sleep Chronotherapy Impact of circadian rhythms on sleep, physiology, cognition and health Mechanisms controlling circadian rhythms, centrally and peripherally Impact of circadian rhythm disruptions (including night shift work, jet lag and social jet lag) on sleep, physiology, cognition and health Behavioral and pharmacological interventions aimed at reducing adverse effects of circadian-related sleep disruption Assessment of technologies and biomarkers for measuring sleep and/or circadian rhythms Epigenetic markers of sleep or circadian disruption.